[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346007-105":59,"doc-detail-346007-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","select-novel-small-molecule-upa-potential-inhibitors-as-anti-cancer-agents-against-breast-cancer","Select novel small-molecule uPA potential inhibitors as anti-cancer agents against breast cancer","","Cancer metastasis drives global morbidity and mortality, and the urokinase-type plasminogen activator (uPA) with its receptor (uPAR) supports abnormal cell spread and tumor progression. This study evaluates novel uPA/uPAR small-molecule compounds as anticancer targets across tumor types, screening inhibitory bioactivity against uPA and receptor interactions. Several compounds showed low IC₅₀ values, including activity down to 1.4 μM against MDA-MB-231 triple negative breast cancer, with KCO241 and KCO246 inducing apoptosis and selective efficacy. The work suggests therapeutic potential for metastatic cancers and supports further preclinical in vivo safety, pharmacology, and translational assessment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/select-novel-small-molecule-upa-potential-inhibitors-as-anti-cancer-agents-against-breast-cancer/346007/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/select-novel-small-molecule-upa-potential-inhibitors-as-anti-cancer-agents-against-breast-cancer/346007.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biological role does uPA/uPAR play in cancer progression?","Question",{"text":112,"@type":113},"uPA and uPAR facilitate abnormal cell metastasis and tumor progression by activating plasminogen to plasmin and triggering downstream signaling that promotes invasion and ECM degradation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What evidence supports the anticancer potential of the novel compounds?",{"text":117,"@type":113},"Screened compounds showed inhibitory activity on uPA and receptor interactions with low IC₅₀ values, including activity against the MDA-MB-231 triple negative breast cancer cell line, alongside induction of apoptotic pathways.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the study’s findings relate to metastatic breast cancer treatment?",{"text":121,"@type":113},"The results indicate selective anticancer efficacy and suggest that targeting uPA inhibitors may help modulate disease progression and provide therapeutic potential against metastatic cancers, pending further in vivo evaluation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346007,1790178515,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSelect novel small-molecule uPA potential inhibitors as anti-cancer agents against breast cancer  \nNadinAlmosnid1,2􀀍, Imadul Islam2, Rizwan Ali2, Shatha Algheribe2,  \nRabih O. Al-Kaysi1,2, Sarah Huwaizi2, RehamA. Abed1, Dalal Aldeghaither1,2, Mohmed Boudjelal2, Nosaibah Samman2,3, Nimer Mehyar1,2,3 & NorahAlruwaili1,2  \nCancer metastasis is a significant contributor to global morbidity and mortality rates. The urokinase type plasminogen activator (uPA) and its receptor (uPAR) play an essential role in facilitating abnormal cell metastasis and tumor progression. This research examines novel uPA/uPAR compounds as potential anticancer targets in various types of tumors. Several compounds were screened for their bioactivity and inhibitory effects on uPA and its receptor interactions, demonstrating the significant potential of a compound previously recognized as a promising uPA inhibitor, initially developed for the treatment of multiple sclerosis. The compounds exhibited notably low IC₅₀ values, as low as 1.4 μM, against the aggressive triple negative breast cancer cell line MDA-MB-231 compared to the chemotherapeutic drug Mitoxantrone. MDA-MB-231 cells treated with KCO241 and KCO246 exhibited selective anticancer activity, inducing apoptotic pathways and demonstrating selective anticancer efficacy. This study showed that these novel uPA inhibitors have potential therapeutic applications for the treatment of metastatic cancers and the modulation of disease progression. Subsequent preclinical in vivo investigations will further evaluate the safety as well as pharmacological characteristics and potential for translation.  \nKeywords Urokinase plasminogen activator, uPA, Breast cancer, Metastasis, Inhibitors  \nAbbreviations  \nIC 50  \nuPA  \nuPAR  \nMDA-MB-231 ECM  \nMCF7  \nHCT8  \nKAIMRC2  \nKAIMRC1  \nHalf-maximal inhibitory concentration The urokinase type plasminogen activator (uPA) Urokinase plasminogen activator surface receptor Triple negative breast cancer cell line Extracellular matrix (ECM)  \nHuman breast carcinoma  \nHuman colorectal cancer cell line  \nKAIMRC2 (naturally immortalized breast cancer) KAIMRC1 (Breast carcinoma cell line)  \nUrokinase-type plasminogen activator uPA, a serine protease enzyme belonging to the trypsin family, is involved in many biological processes1. This enzyme system is responsible for activating plasminogen to plasmin, which plays a central role in tumor biology and represents a potential target for therapeutic intervention in tumor progression and metastasis in several forms of cancer. In the early and late 2000s, uPA attracted much attention as a cancer target and was implicated in the invasion and spread of tumors in several aggressive cancers, including triple-negative breast, pancreatic, gastric, colorectal, and prostate cancers2–6. The expression of uPA components differs in cancer cells compared to normal tissues and has become an essential biomarker in various cancer types7. In 2007, the American Society of Clinical Oncology recommended the use of the invasion marker uPA and its inhibitors, PAI-1, for risk management8,9.Therefore, uPA and its associated pathways can be investigated further to develop novel therapy against cancer. Generally, uPA overexpression has been associated with metastatic solid tumors10.  \n1Department of Basic Sciences, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. 2Medical Research Core Facility and Platforms (MRCFP), King Abdullah International Medical Research Center (KAIMRC), P.O. Box 22490, 11426 Riyadh, Saudi Arabia. 3King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia. 􀀍 email: [mosnidn@ksau-hs.edu.sa](mosnidn@ksau-hs.edu.sa)  \nTo impede enzyme activity, various techniques have been employed, including gene knockout11, recombinant DNA technology12, and modulation of macrop","cbCaiotKw56mX8BV","https://ap.wps.com/l/cbCaiotKw56mX8BV","pdf",3659503,"English","# Keywords\n# Abbreviations\n## uPA system and role in tumor biology\n## Mechanisms and therapeutic targeting\n## Experimental rationale and pathway overview\n## Clinical and prognostic associations","[{\"question\":\"What biological role does uPA/uPAR play in cancer progression?\",\"answer\":\"uPA and uPAR facilitate abnormal cell metastasis and tumor progression by activating plasminogen to plasmin and triggering downstream signaling that promotes invasion and ECM degradation.\"},{\"question\":\"What evidence supports the anticancer potential of the novel compounds?\",\"answer\":\"Screened compounds showed inhibitory activity on uPA and receptor interactions with low IC₅₀ values, including activity against the MDA-MB-231 triple negative breast cancer cell line, alongside induction of apoptotic pathways.\"},{\"question\":\"How do the study’s findings relate to metastatic breast cancer treatment?\",\"answer\":\"The results indicate selective anticancer efficacy and suggest that targeting uPA inhibitors may help modulate disease progression and provide therapeutic potential against metastatic cancers, pending further in vivo evaluation.\"}]","Select novel small-molecule uPA potential inhibitors as anti-cancer agents against breast cancer | PDF",1790059656,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97d215dfef881eba7caafb1a8e00bcd7.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fa6491692431ef2c0b6bdfa731e7e02.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d35029903494d1889b46d32d0cce4cc.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f85b30a53fb3f25651fc14cedbd25f63.webp",980,1287]